Novel Migraine Treatments: A Review

Aims: To present a review of the mechanisms of action, available clinical data, and safety profiles of novel migraine therapeutics to inform practice. Methods: PubMed, Medline, and Google Scholar were searched for randomized controlled trials (24 publications), review articles (15 publications), and other pertinent literature (16 publications) discussing the novel migraine therapeutics available between the years 2010 and 2021. All publications were reviewed to assess the mechanism of action, relevant clinical data, and side effect profile for each novel treatment. Therapeutic gain was also recorded in studies that included a placebo arm. Results: A total of 55 studies were included in the final analysis. In the preventive treatment of migraine, novel medications target calcitonin gene-related peptide (CGRP) and fall into either the monoclonal anti-CGRP or gepant class. For the acute treatment of migraine, novel medications fall into either the ditan or gepant class. Several medical devices have been developed for the acute and preventive treatment of migraine. Conclusion: Novel therapeutics are available for both the prevention and acute treatment of migraine headaches. These new medications and neuromodulatory devices appear overall to be safe and effective in the management of migraine headaches.

1. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia 2018;38:1–211.

2. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003;4:386–398.

3. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999;159:813–818.

4. Ruthirago D, Julayanont P, Kim J. Translational correlation: Migraine. In: Michael Conn P (ed). Conn’s Translational Neuroscience. London: Academic Press, 2017:159–165.

5. de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase I, ran-domized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and pa-tients with migraine. Clin Pharmacol Ther 2018;105:815–825.

6. Khan S, Amin FM, Christensen CE, et al. Meningeal contribution to migraine pain: A magnetic resonance angiography study. Brain 2019;142:93–102.

7. Markham A. Erenumab: First global approval. Drugs 2018;78:1157–1161.

8. Goadsby PJ, Reuter U, Bonner J, et al. Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial. J Neurology, Neurosurgery & Psychiatry 2017;88:e1.

9. Tepper SJ, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16:425–434.

10. Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenum-ab for migraine prevention. Neurology 2020;94:e497–e510.

11. Ashina M, Goadsby PJ, Reuter U, et al. Long-term safe-ty and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 2019;39:1455–1464.

12. Dodick DW, Tepper SJ, Ailani J, et al. Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. Headache 2021;61:1411–1420.

13. Dodick DW. CGRP ligand and receptor monoclonal anti-bodies for migraine prevention: Evidence review and clinical implications. Cephalalgia 2019;39:445–458.

14. Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab—a humanized monoclonal anti-CGRP antibody—inhibits thinly my-elinated (Aδ) but not unmyelinated (C) meningeal nociceptors. J Neurosci 2017;37:10587–10596.

15. Yuan H, Spare NM, and Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: A narrative review. Headache 2019;59(suppl 2):20–32.

16. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim B-K, Yang JY, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 2018;38:1442–1454.

17. Detke HC, Goadsby PJ, Wang S, Friedman DI, Salzler KJ, Aurora SK, et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018;91:e2211–e2221.

18. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of freman-ezumab compared with placebo for prevention of episodic mi-graine: A randomized clinical trial. JAMA 2018;319:1999–2008.

19. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017;377:2113–2122.

20. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic mi-graine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020;40:241–254.

21. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. N eurology 2020;94:e1365–e1377.

22. Maasumi K, Michael RL, Rapoport AM. CGRP and migraine: The role of blocking calcitonin gene-related peptide ligand and recep-tor in the management of migraine. Drugs 2018;78:913–928.

23. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 2010;24:539–548.

24. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for pre-ventive treatment of migraine: A phase 2/3, randomised, dou-ble-blind, placebo-controlled trial. Lancet 2021;397:51–60.

25. Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: A double-blind, randomised phase 2b/3 trial. Lancet Neurol 2020;19:727–737.

26. Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preven-tive treatment of migraine. N Engl J Med 2021;385:695–706.

27. Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug–drug interactions of new anti-migraine drugs—lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics 2020;12:1180.

28. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical phar-macological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010;30:1159–1169.

29. Färkkilä M, Diener H-C, Géraud G, et al. Efficacy and toler-ability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, place-bo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405–413.

30. de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT be-yond the triptans. Pharmacol Ther 2020;211:107528.

31. Tepper SJ, Krege JH, Lombard L, et al. Characterization of dizziness after lasmiditan usage: Findings from the SAMURAI and SPARTAN acute migraine treatment randomized tri-als. Headache 2019;59:1052–1062.

32. Tepper SJ, Vasudeva R, Krege JH, et al. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of diffi-cult-to-treat migraine attacks. Headache 2020;60:1601–1615.

33. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 ran-domized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 2019;142:1894–1904.

34. Pearlman EM, Wilbraham D, Dennehy EB, et al. Effects of las-miditan on simulated driving performance: Results of two ran-domized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol 2020;35:e2732.

35. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treat-ment of migraine. N Engl J Med 2019;381:2230–2241.

36. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tol-erability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial. Lancet 2019;394:737–745.

37. Riederer F, Penning S, Schoenen J. Transcutaneous supra-orbital nerve stimulation (t-SNS) with the Cefaly® device for migraine prevention: A review of the available data. Pain Ther 2015;4:135–147.

38. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology 2013;80:697–704.

39. Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostim-ulation (tSNS) with the Cefaly device in headache treatment: A survey of 2,313 headache sufferers in the general population. J Headache Pain 2013;14:95.

40. Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia 2019;39:3–14.

41. Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone

G. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain 2015;16:61.

42. Morais A, Liu T-T, Qin T, et al. Vagus nerve stimulation inhib-its cortical spreading depression exclusively through central mechanisms. Pain 2020;16:1661–1669.

43. Chen SP, Ay I, Lopes de Morais A, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain 2016;157:797–805.

44. Tassorelli C, Grazzi L, de Tommaso M, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology 2018;91:e364–e373.

45. Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology 2016;87:529–538.

46. Diener H-C, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-con-trolled PREMIUM trial. Cephalalgia 2019;39:1475–1487.

47. Mwamburi M, Tenaglia AT, Leibler EJ, Staats PS. Review of evidence on noninvasive vagus nerve stimulation for treatment of migraine: Efficacy, safety, and implications. Am J Manag Care 2018;24(suppl 24):S507-S516.

48. Barker AT, Shields K. Transcranial magnetic stimulation: Basic principles and clinical applications in migraine. Headache 2017;57:517–524.

49. Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial magnetic stimulation and po-tential cortical and trigeminothalamic mechanisms in migraine. Brain 2016;139:2002–2014.

50. Lipton RB, Dodick DW, Silberstein SD. Single-pulse transcra-nial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-con-trolled trial. Lancet Neurol 2010;9:373–380.

51. Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, pro-spective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018;38:1038–1048.

52. Nir RR, Yarnitsky D. Conditioned pain modulation. Current opinion in supportive and palliative care 2015;9:131–137.

53. Yarnitsky D, Dodick DW, Grosberg BM, et al. Remote electrical neuromodulation (REN) relieves acute migraine: A randomized, double-blind, placebo-controlled, multicenter trial. Headache 2019;59:1240–1252.

54. Nierenburg H, Vieira JR, Lev N, et al. Remote electrical neuromodulation for the acute treatment of migraine in pa-tients with chronic migraine: An open-label pilot study. Pain Ther 2020;9:531–543.

55. Daniel O, Sharon R, Tepper SJ. A device review of Relivion: An external combined occipital and trigeminal neurostimulation (eCOT-NS) system for self-administered treatment of migraine and major depressive disorder. Expert Rev Med Devices 2021;18:333–342.

56. Tepper SJ, Grosberg B, Daniel O, et al. Migraine treatment with external concurrent occipital and trigeminal neurostimulation—A randomized controlled trial. Headache 2022;62:989–1001.